Posted on 9/27/17
Ironwood Pharmaceuticals Struggles With Slump In Sales, Net Losses
Ironwood Pharmaceuticals Inc. (IRWD) stock showed moderate response to the news of FDA approval of its oral fixed dose combination drug, Duzallo. The drug, designed to . . .
Posted on 9/27/17
Tango Therapeutics Named a “Fierce 15” Company by FierceBiotech
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, a biotechnology company creating novel, context-dependent medicines for cancer, today announced that it has been named by FierceBiotech as one of its . . .
Posted on 9/27/17
FierceBiotech Names Magenta Therapeutics as one of its “Fierce 15” Biotech Companies of 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, a biotechnology company developing therapeutics to improve and expand the use of curative hematopoietic stem cell transplantation for more patients, today announced . . .
Posted on 9/26/17
Melinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries
NEW HAVEN, Conn., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced that . . .
Posted on 9/26/17
Bristol-Myers Squibb Achieves Earlier Than Expected Win
Recently, the FDA had approvedBristol-Myers Squibb (BMY) immuno-oncology drug Opdivo, for use in patients with hepatocellular carcinoma (liver cancer) who failed prior therapy. These were patients . . .
Posted on 9/26/17
Why General Electric Company Should Sell Its Healthcare Business
General Electric Company (NYSE:GE) CEO John Flannery has a job to do if he wants to restore investors' confidence in the blue chip industrial stock in . . .
Posted on 9/26/17
Brammer Bio Expands Cell and Gene Therapy Capacity in Florida and Massachusetts
Brammer Bio, a leading cell and gene therapy contract developing and manufacturing organization (CDMO), has confirmed expansions in its early clinical phase facility in Alachua, Florida . . .
Posted on 9/26/17
Sema4 Partners with PWNHealth
STAMFORD, Conn. & SAN DIEGO--(BUSINESS WIRE)--Sema4, a health information company providing advanced genomic testing, and PWNHealth, whose physicians and genetic counselors provide medical oversight and counseling . . .
Posted on 9/26/17
Infinity Pharmaceuticals and Bristol-Myers Squibb Expand Clinical Collaboration
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has expanded its existing clinical collaboration with Bristol-Myers Squibb evaluating IPI-549 in combination with Opdivo® to include . . .
Posted on 9/25/17
Boston Scientific Announces U.S. FDA Approval for MRI Labeling on High-Voltage Devices and U.S. Launch of Resonate Devices with the HeartLogic Heart Failure Diagnostic
Boston Scientific (NYSE: BSX) has launched the Resonate family of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) systems featuring the HeartLogic Heart Failure . . .
Posted on 9/25/17
Could This Be Warren Buffett's Greatest Weakness?
Warren Buffett is, without question, one of the greatest investors of all time. Over the past 50 years, the company he runs, Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B), . . .
Posted on 9/24/17
Eleven Biotherapeutics Announces Completion of Vicinium Manufacturing
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that . . .
Posted on 9/21/17
Evariant to Showcase Leading Patient Acquisition and Retention Solutions at SHSMD Connections 2017
FARMINGTON, Conn.--(BUSINESS WIRE)--Evariant, the leading healthcare CRM data analytics platform, announced today it is a Diamond Sponsor of SHSMD Connections 2017, the premier conference for healthcare . . .
Posted on 9/21/17
Aldeyra Therapeutics Closes Public Offering of Common Stock
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, . . .
Posted on 9/21/17
Landos Biopharma Raises $10M Series A Led by Perceptive Advisors
Landos Biopharma, Inc., an emerging biopharmaceutical company focused on developing improved treatments for
Posted on 9/21/17
AVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in
CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA®(tivozanib), . . .
Posted on 9/20/17
Boston Scientific May Pull Synergy Stent Out Of India
Bloomberg reports that Boston Scientific (NYSE:BSX) is considering withdrawing its high-end Synergy stent from India due to price concerns. Company representatives met with the National Pricing . . .
Posted on 9/20/17
Aldeyra Therapeutics Prices Public Offering of Common Stock
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, . . .
Posted on 9/20/17
Acceleron Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare hematologic, neuromuscular, . . .
Posted on 9/19/17
Call for Speakers Announced for 2018 Emerging Trends in Wellness Conference
Wellness Workdays, a leading provider of corporate wellness programs, announces its “Call for Speakers” for the 2018 Emerging Trends in Wellness Conference April 11-12 outside of . . .
Posted on 9/19/17
Epizyme Closes Public Offering
CAMBRIDGE, Mass., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the closing of its public . . .
Posted on 9/19/17
Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?
Billionaire George Soros is an iconic figure in the world of investing because of his unique ability to consistently beat the broader markets. As such, the . . .
Posted on 9/19/17
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
There is perhaps no scarier word in the English language than "cancer." More than 15.5 million Americans who were alive as of Jan. 1, 2016, have . . .
Posted on 9/19/17
Deciphera Pharmaceuticals Sets Terms For $100 Million IPO
Quick TakeDeciphera Pharmaceuticals (DCPH) has set terms for its proposed IPO, seeking to sell 6.25 million of common stock at a midpoint price of $16.00 per . . .
Posted on 9/19/17
Analyst: Berkshire Hathaway Stock Is a Buy
JPMorgan analyst Sarah Dewitt just started coverage on famed investor Warren Buffett's Berkshire Hathaway (NYSE:BRK-B) (NYSE:BRK-A), starting the stock with a buy rating. The analyst's optimistic . . .
Boston
